Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists
- 1 October 2014
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 22 (19) , 5428-5445
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Discovery of (3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and NephropathyJournal of Medicinal Chemistry, 2010
- Non-steroidal mineralocorticoid receptor antagonistsExpert Opinion on Therapeutic Patents, 2007
- Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockadeNature Clinical Practice Nephrology, 2007
- Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium HomeostasisHeart Failure Reviews, 2005
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Cardiac Steroidogenesis in the Normal and Failing HeartThe Journal of Clinical Endocrinology & Metabolism, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Molecular Biology of Mineralocorticoid MetabolismAnnual Review of Nutrition, 1996
- Antialdosterones: Incidence and prevention of sexual side effectsJournal of Steroid Biochemistry, 1989